The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Interim efficacy results of daratumumab versus lenalidomide maintenance in newly diagnosed myeloma
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides insight into the interim efficacy results of a randomized clinical trial (NCT04497961) evaluating single-agent daratumumab versus the current standard-of-care lenalidomide as a maintenance strategy in patients with newly diagnosed multiple myeloma (MM). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
This is an investigator-initiated clinical trial looking at a primary endpoint of quality of life between two maintenance strategies, daratumumab versus lenalidomide. It’s a 100 patient study with 50 patients to be enrolled in each arm. Currently, the study is about 85% enrolled and we present interim efficacy analysis. So that’s a secondary endpoint. The primary endpoint of quality of life we are not presenting at ASH at this time...
This is an investigator-initiated clinical trial looking at a primary endpoint of quality of life between two maintenance strategies, daratumumab versus lenalidomide. It’s a 100 patient study with 50 patients to be enrolled in each arm. Currently, the study is about 85% enrolled and we present interim efficacy analysis. So that’s a secondary endpoint. The primary endpoint of quality of life we are not presenting at ASH at this time.
In terms of the secondary endpoint, what we do see is that both arms have single agent daratumumab and single agent lenalidomide given after induction and transplant as maintenance, plus minus transplant, so whether they got a transplant or not, showed similar progression-free survival at one year and two years, and also MRD negativity rates, suggesting that daratumumab may be an effective maintenance strategy as well as a single agent in patients, especially that may have intolerance to revlamide or lenalidomide and side effects.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Sanofi: Honoraria; Bristol Myers Squibb: Research Funding; Janssen: Honoraria, Research Funding.
